Worth reading
69In focus
Scored from 2 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
0
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Issuance through a third-party allotment of the 23rd and 24th Series Stock Acquisition Rights (with exercise price adjustment and exercise suspension provisions)
Intended allottee
EVO FUND
発行済株式総数
Exercise ratio for the month: 0% (0 rights exercised for both the 23rd and 24th Series)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
¥637 for the 23rd Series and ¥777 for the 24th Series. The rights include an exercise price adjustment provision, but the adjustment floor is not disclosed.
Number of Stock Acquisition Rights
Total issued: 1,050,000 rights for the 23rd Series and 1,050,000 rights for the 24th Series. Unexercised balance as of the end of March 2026: 1,050,000 rights (105,000,000 shares) for the 23rd Series and 1,050,000 rights (105,000,000 shares) for the 24th Series
Procedures under the Corporate Code of Conduct
The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations
Most recent equity financing
Timing 8 December 2025 / Type Issuance of the 23rd to 24th Series Stock Acquisition Rights (with exercise price adjustment and exercise suspension provisions) through an allotment to EVO FUND / Amount Not disclosed
| Item | Details |
|---|---|
| Type of issuance or disposal | Issuance through a third-party allotment of the 23rd and 24th Series Stock Acquisition Rights (with exercise price adjustment and exercise suspension provisions) |
| Intended allottee | EVO FUND |
| Dilution Rate | Exercise ratio for the month: 0% (0 rights exercised for both the 23rd and 24th Series) |
| Total number of issued shares | 1,142,274,340 shares (number of listed shares as of the payment date for the issuance) → Not disclosed |
| Exercise price | ¥637 for the 23rd Series and ¥777 for the 24th Series. The rights include an exercise price adjustment provision, but the adjustment floor is not disclosed. |
| Number of Stock Acquisition Rights | Total issued: 1,050,000 rights for the 23rd Series and 1,050,000 rights for the 24th Series. Unexercised balance as of the end of March 2026: 1,050,000 rights (105,000,000 shares) for the 23rd Series and 1,050,000 rights (105,000,000 shares) for the 24th Series |
| Procedures under the Corporate Code of Conduct | The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations |
| Most recent equity financing | Timing 8 December 2025 / Type Issuance of the 23rd to 24th Series Stock Acquisition Rights (with exercise price adjustment and exercise suspension provisions) through an allotment to EVO FUND / Amount Not disclosed |
Items this document does not state (20)
Number of shares to be issued or disposed ofIssue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Exercise has been suspended from 24 March 2026 through 8 December 2027 pursuant to the exercise suspension provisions.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.